{"title":"Predicting vulnerability status of carotid plaques using CTA-based quantitative analysis.","authors":"Qun Lao, Rongzhen Zhou, Yitian Wu, ChangFeng Feng, Jianxin Pang, Ling Ma, Yunjun Yang, Wenbin Ji","doi":"10.1097/FJC.0000000000001664","DOIUrl":null,"url":null,"abstract":"<p><p>The study aimed to develop a radiomics model to assess carotid artery plaque vulnerability using CTA images. It retrospectively included 107 patients with carotid artery stenosis who underwent carotid artery stenting (CAS) from 2017 to 2022. Patients were categorized into stable and vulnerable plaque groups based on pathology. A training group and a testing group were formed in a 7:3 ratio. Clinical data, including demographics and lipid profiles, were collected alongside pre-treatment CTA images. Radiomics features were extracted and reduced using the LASSO method to minimize redundancy. A radiomics model was then constructed, utilizing 13 features with a minimum penalty coefficient logλ=0.047. Significant differences were found between stable and vulnerable plaques in terms of stenosis degree. The radiomics model showed high accuracy (AUC of 0.959 in training and 0.942 in testing) for identifying vulnerable plaques. When combined with clinical parameters stenosis degree, the model's diagnostic efficacy improved further, with AUC values of 0.985 and 0.961 in the training and testing groups, respectively. Decision curve analysis (DCA) indicated that the combined model offered superior clinical benefits over the clinical model and radiomics model alone. The study concludes that the combined radiomics model, incorporating stenosis degree, presents a promising tool for differentiating vulnerable from stable plaques.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001664","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
The study aimed to develop a radiomics model to assess carotid artery plaque vulnerability using CTA images. It retrospectively included 107 patients with carotid artery stenosis who underwent carotid artery stenting (CAS) from 2017 to 2022. Patients were categorized into stable and vulnerable plaque groups based on pathology. A training group and a testing group were formed in a 7:3 ratio. Clinical data, including demographics and lipid profiles, were collected alongside pre-treatment CTA images. Radiomics features were extracted and reduced using the LASSO method to minimize redundancy. A radiomics model was then constructed, utilizing 13 features with a minimum penalty coefficient logλ=0.047. Significant differences were found between stable and vulnerable plaques in terms of stenosis degree. The radiomics model showed high accuracy (AUC of 0.959 in training and 0.942 in testing) for identifying vulnerable plaques. When combined with clinical parameters stenosis degree, the model's diagnostic efficacy improved further, with AUC values of 0.985 and 0.961 in the training and testing groups, respectively. Decision curve analysis (DCA) indicated that the combined model offered superior clinical benefits over the clinical model and radiomics model alone. The study concludes that the combined radiomics model, incorporating stenosis degree, presents a promising tool for differentiating vulnerable from stable plaques.
期刊介绍:
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.
Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.